ifosfamide has been researched along with African Lymphoma in 47 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported." | 7.76 | Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with ( Azuma, T; Kim, SW; Kobayashi, Y; Maeshima, AM; Maruyama, D; Matsuno, Y; Mori, M; Munakata, W; Nomoto, J; Taniguchi, H; Tobinai, K; Watanabe, T, 2010) |
| "The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients." | 5.20 | AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. ( Ambinder, R; Baiocchi, R; Cesarman, E; Kaplan, L; Lee, JY; Noy, A; Ratner, L; Reid, E; Wagner-Johnston, N, 2015) |
| " In this case report, we treated a 20-year-old male patient with cyclophosphamide, doxorubicin, vincristine, dexamethasone, and methotrexate and cytarabine chemotherapy following a diagnosis of Stage IV Burkitt lymphoma." | 4.89 | Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma. ( Choi, KH; Hyun, JY; Kim, JH; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, JY; Lim, SH, 2013) |
| "The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported." | 3.76 | Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with ( Azuma, T; Kim, SW; Kobayashi, Y; Maeshima, AM; Maruyama, D; Matsuno, Y; Mori, M; Munakata, W; Nomoto, J; Taniguchi, H; Tobinai, K; Watanabe, T, 2010) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | 2.68 | Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| "Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene." | 2.44 | Adult Burkitt lymphoma: advances in diagnosis and treatment. ( Aldoss, IT; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Fu, K; Vose, JM; Weisenburger, DD, 2008) |
| "Ifosfamide is a chemotherapy agent commonly used in the treatment of several solid tumors and hematologic malignancies." | 2.44 | Ifosfamide neuropsychiatric toxicity in patients with cancer. ( Alici-Evcimen, Y; Breitbart, WS, 2007) |
| "Ifosfamide is an alkylating agent with a broad spectrum of activity in solid tumors and hematological malignancies." | 2.42 | Ifosfamide in hematological malignancies of adults. ( Elice, F; Rodeghiero, F, 2003) |
| "Treatment options for Burkitt's lymphoma involve complex chemotherapy regimens that contain as many as 10 cytotoxic agents." | 2.41 | Challenges in the management of Burkitt's lymphoma. ( Levine, AM, 2002) |
| "Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas." | 1.48 | Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. ( Baars, JW; Brouwer, R; Chamuleau, MED; de Jong, D; de Wreede, LC; Demandt, AMP; Doorduijn, JK; Hardi, L; Kersten, MJ; Kluin, PM; Nijland, M; Oosten, LEM; Siemes, C; Smeekes, OS; Stevens, WBC; Thielen, FW; Uyl-de Groot, CA; van Imhoff, GW; Veelken, H, 2018) |
| "Treatment of Burkitt lymphoma (BL) with intensive, multi-agent chemotherapy with aggressive central nervous system (CNS) prophylaxis results in high cure rates, although no regimen is standard of care." | 1.48 | Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. ( Abou Mourad, Y; Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Gerrie, AS; Hogge, DE; Leitch, H; Nantel, SH; Narayanan, S; Nevill, TJ; Power, MM; Ramadan, K; Sanford, DS; Sehn, LH; Slack, GW; Song, KW; Sutherland, HJ; Toze, CL; Tucker, T; Zhu, KY, 2018) |
| " Much attention has focussed on pharmacokinetic interactions attributable to effects on hepatic microsomal enzymes, but not on competition for the renal organic anion transport system." | 1.43 | The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. ( Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016) |
| "We report a case of HIV-negative Burkitt lymphoma (BL) that relapsed 9 years after complete remission." | 1.42 | A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission. ( Ando, K; Kikuchi, T; Kikuti, YY; Kojima, M; Moriuchi, M; Murayama, H; Nakamura, N; Ogawa, Y; Tokunaka, M; Tsuboi, K; Yabe, M, 2015) |
| "Standard treatment of adult Burkitt lymphoma is not defined due to the lack of randomised trials." | 1.39 | Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. ( Brown, PN; D'Amore, F; Hagberg, H; Hagberg, O; Jerkeman, M; Pedersen, LM; Wästerlid, T, 2013) |
| "We report a case of CD20 Burkitt leukemia with inverted duplication (1q) mutation, who had an early relapse during NHL-BFM 95 treatment." | 1.38 | Successful treatment of ICE-rituximab chemotherapy and subsequent bone marrow transplantation in a patient with early-relapse Burkitt leukemia and inverted duplication of 1q. ( Avci, Z; Gursel, O; Kurekci, E; Malbora, B; Olgac, A; Ozbek, N, 2012) |
| "The patient was diagnosed as having Burkitt's lymphoma (BL) with t(8;14) and t(14;18)." | 1.34 | [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy]. ( Fujishima, M; Fujishima, N; Hirokawa, M; Inomata, M; Kameoka, Y; Saitoh, H; Saitoh, K; Sawada, K; Takahashi, N; Yamanaka, Y; Yoshioka, T, 2007) |
| "The efficacy of CHOP regimen on Burkitt's lymphoma is poor." | 1.34 | [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. ( Chen, XQ; Guan, ZZ; He, YJ; Lin, H; Ling, JY; Liu, DG; Luo, WB; Sun, XF; Xia, Y; Xiang, XJ; Zhen, ZJ; Zheng, L, 2007) |
| "He was given a diagnosis of Burkitt's lymphoma and was in clinical stage II B." | 1.30 | [Successful treatment with high dose chemotherapy following peripheral blood stem cell transplantation for relapsed Burkitt's lymphoma with central nervous system involvement]. ( Kondo, E; Miura, A; Mizuno, H; Yamao, H; Yuge, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.77) | 18.2507 |
| 2000's | 18 (38.30) | 29.6817 |
| 2010's | 20 (42.55) | 24.3611 |
| 2020's | 3 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, T | 1 |
| Sahu, S | 1 |
| Sharma, MC | 1 |
| Borkar, S | 1 |
| McMillan, AK | 1 |
| Phillips, EH | 1 |
| Kirkwood, AA | 1 |
| Barrans, S | 1 |
| Burton, C | 1 |
| Rule, S | 1 |
| Patmore, R | 1 |
| Pettengell, R | 1 |
| Ardeshna, KM | 1 |
| Lawrie, A | 1 |
| Montoto, S | 1 |
| Paneesha, S | 1 |
| Clifton-Hadley, L | 1 |
| Linch, DC | 1 |
| Colton, BS | 1 |
| Hornstein, N | 1 |
| Timmerman, J | 1 |
| Larson, S | 1 |
| Glaspy, J | 1 |
| Oosten, LEM | 1 |
| Chamuleau, MED | 1 |
| Thielen, FW | 1 |
| de Wreede, LC | 1 |
| Siemes, C | 1 |
| Doorduijn, JK | 1 |
| Smeekes, OS | 1 |
| Kersten, MJ | 1 |
| Hardi, L | 1 |
| Baars, JW | 1 |
| Demandt, AMP | 1 |
| Stevens, WBC | 1 |
| Nijland, M | 1 |
| van Imhoff, GW | 1 |
| Brouwer, R | 1 |
| Uyl-de Groot, CA | 1 |
| Kluin, PM | 1 |
| de Jong, D | 1 |
| Veelken, H | 1 |
| Zhu, KY | 1 |
| Song, KW | 1 |
| Connors, JM | 1 |
| Leitch, H | 1 |
| Barnett, MJ | 1 |
| Ramadan, K | 1 |
| Slack, GW | 1 |
| Abou Mourad, Y | 1 |
| Forrest, DL | 1 |
| Hogge, DE | 1 |
| Nantel, SH | 1 |
| Narayanan, S | 1 |
| Nevill, TJ | 1 |
| Power, MM | 1 |
| Sanford, DS | 1 |
| Sutherland, HJ | 1 |
| Tucker, T | 1 |
| Toze, CL | 1 |
| Sehn, LH | 1 |
| Broady, R | 1 |
| Gerrie, AS | 1 |
| Rigaud, C | 1 |
| Auperin, A | 1 |
| Jourdain, A | 1 |
| Haouy, S | 1 |
| Couec, ML | 1 |
| Aladjidi, N | 1 |
| Gandemer, V | 1 |
| Lambliotte, A | 1 |
| Plat, G | 1 |
| Landman-Parker, J | 1 |
| Michon, J | 1 |
| Leblanc, T | 1 |
| Patte, C | 1 |
| Minard-Colin, V | 1 |
| Wästerlid, T | 1 |
| Brown, PN | 1 |
| Hagberg, O | 1 |
| Hagberg, H | 1 |
| Pedersen, LM | 1 |
| D'Amore, F | 1 |
| Jerkeman, M | 1 |
| Lim, SH | 1 |
| Lee, JY | 3 |
| Kim, JH | 1 |
| Choi, KH | 1 |
| Hyun, JY | 1 |
| Ko, YH | 1 |
| Lee, J | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Evens, AM | 1 |
| Carson, KR | 1 |
| Kolesar, J | 1 |
| Nabhan, C | 2 |
| Helenowski, I | 1 |
| Islam, N | 1 |
| Jovanovic, B | 1 |
| Barr, PM | 1 |
| Caimi, PF | 1 |
| Gregory, SA | 1 |
| Gordon, LI | 1 |
| Kojima, Y | 1 |
| Hagiwara, S | 1 |
| Uehira, T | 1 |
| Ajisawa, A | 1 |
| Kitanaka, A | 1 |
| Tanuma, J | 1 |
| Okada, S | 1 |
| Nagai, H | 1 |
| Jacobson, C | 1 |
| LaCasce, A | 2 |
| Maruyama, D | 3 |
| Hoelzer, D | 3 |
| Walewski, J | 3 |
| Döhner, H | 1 |
| Viardot, A | 1 |
| Hiddemann, W | 2 |
| Spiekermann, K | 1 |
| Serve, H | 1 |
| Dührsen, U | 1 |
| Hüttmann, A | 1 |
| Thiel, E | 2 |
| Dengler, J | 1 |
| Kneba, M | 1 |
| Schaich, M | 1 |
| Schmidt-Wolf, IG | 2 |
| Beck, J | 1 |
| Hertenstein, B | 1 |
| Reichle, A | 1 |
| Domanska-Czyz, K | 1 |
| Fietkau, R | 1 |
| Horst, HA | 1 |
| Rieder, H | 2 |
| Schwartz, S | 1 |
| Burmeister, T | 1 |
| Gökbuget, N | 2 |
| Kojima, M | 1 |
| Nakamura, N | 1 |
| Yabe, M | 1 |
| Tokunaka, M | 1 |
| Kikuti, YY | 1 |
| Kikuchi, T | 1 |
| Murayama, H | 1 |
| Moriuchi, M | 1 |
| Tsuboi, K | 1 |
| Ogawa, Y | 1 |
| Ando, K | 1 |
| Noy, A | 2 |
| Cesarman, E | 1 |
| Ambinder, R | 1 |
| Baiocchi, R | 1 |
| Reid, E | 1 |
| Ratner, L | 1 |
| Wagner-Johnston, N | 1 |
| Kaplan, L | 1 |
| Landsburg, DJ | 1 |
| Petrich, AM | 1 |
| Abramson, JS | 2 |
| Sohani, AR | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Chavez, JC | 1 |
| Song, K | 1 |
| Zelenetz, AD | 2 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Fenske, TS | 1 |
| Jaso, J | 1 |
| Medeiros, LJ | 1 |
| Yang, DT | 1 |
| Dalla Pria, A | 1 |
| Bendle, M | 1 |
| Ramaswami, R | 1 |
| Boffito, M | 1 |
| Bower, M | 1 |
| Mead, GM | 2 |
| Barrans, SL | 1 |
| Qian, W | 1 |
| Radford, JA | 1 |
| Wolf, M | 1 |
| Clawson, SM | 1 |
| Stenning, SP | 2 |
| Yule, CL | 1 |
| Jack, AS | 1 |
| Aldoss, IT | 1 |
| Weisenburger, DD | 1 |
| Fu, K | 1 |
| Chan, WC | 1 |
| Vose, JM | 1 |
| Bierman, PJ | 1 |
| Bociek, RG | 1 |
| Armitage, JO | 1 |
| Tauro, S | 1 |
| Cochrane, L | 1 |
| Lauritzsen, GF | 1 |
| Baker, L | 1 |
| Delabie, J | 1 |
| Roberts, C | 1 |
| Mahendra, P | 1 |
| Holte, H | 1 |
| Watanabe, T | 1 |
| Maeshima, AM | 1 |
| Nomoto, J | 1 |
| Taniguchi, H | 1 |
| Azuma, T | 1 |
| Mori, M | 1 |
| Munakata, W | 1 |
| Kim, SW | 1 |
| Kobayashi, Y | 1 |
| Matsuno, Y | 1 |
| Tobinai, K | 1 |
| Barnes, JA | 1 |
| Lacasce, AS | 1 |
| Feng, Y | 1 |
| Toomey, CE | 1 |
| Neuberg, D | 2 |
| Michaelson, JS | 1 |
| Hochberg, EP | 1 |
| Malbora, B | 1 |
| Avci, Z | 1 |
| Olgac, A | 1 |
| Gursel, O | 1 |
| Kurekci, E | 1 |
| Ozbek, N | 1 |
| Ngoma, T | 1 |
| Adde, M | 1 |
| Durosinmi, M | 1 |
| Githang'a, J | 1 |
| Aken'Ova, Y | 1 |
| Kaijage, J | 1 |
| Adeodou, O | 1 |
| Rajab, J | 1 |
| Brown, BJ | 1 |
| Leoncini, L | 1 |
| Naresh, K | 1 |
| Raphael, M | 1 |
| Hurwitz, N | 1 |
| Scanlan, P | 1 |
| Rohatiner, A | 1 |
| Venzon, D | 1 |
| Magrath, I | 1 |
| Sydes, MR | 1 |
| Grigg, A | 1 |
| Hatton, CS | 1 |
| Pescosta, N | 1 |
| Guarnaccia, C | 1 |
| Lewis, MS | 1 |
| McKendrick, J | 1 |
| Wright, D | 1 |
| Norbert, P | 1 |
| Levine, AM | 1 |
| Mottl, H | 1 |
| Bajciova, V | 1 |
| Nemec, J | 1 |
| Al Shemmari, S | 1 |
| Al Awadi, S | 1 |
| Wang, ES | 1 |
| Straus, DJ | 1 |
| Teruya-Feldstein, J | 1 |
| Qin, J | 1 |
| Portlock, C | 1 |
| Moskowitz, C | 1 |
| Goy, A | 1 |
| Hedrick, E | 1 |
| Xicoy, B | 1 |
| Ribera, JM | 1 |
| Esteve, J | 1 |
| Brunet, S | 1 |
| Sanz, MA | 1 |
| Fernández-Abellán, P | 1 |
| Feliu, E | 1 |
| Rodeghiero, F | 1 |
| Elice, F | 1 |
| Howard, O | 1 |
| Lib, S | 1 |
| Fisher, D | 1 |
| Weng, A | 1 |
| Shipp, M | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Lam, MS | 1 |
| Alici-Evcimen, Y | 1 |
| Breitbart, WS | 1 |
| Moleti, ML | 1 |
| Testi, AM | 1 |
| Giona, F | 1 |
| Malandruccolo, L | 1 |
| Pescarmona, E | 1 |
| Martino, P | 1 |
| Paoloni, F | 1 |
| Barberi, W | 1 |
| Palumbo, G | 1 |
| Mandelli, F | 1 |
| Foa, R | 1 |
| Fujishima, N | 1 |
| Fujishima, M | 1 |
| Inomata, M | 1 |
| Yamanaka, Y | 1 |
| Saitoh, K | 1 |
| Kameoka, Y | 1 |
| Yoshioka, T | 1 |
| Saitoh, H | 1 |
| Takahashi, N | 1 |
| Hirokawa, M | 1 |
| Sawada, K | 1 |
| Shimomura, A | 1 |
| Lilienfeld-Toal, Mv | 1 |
| Balta, Z | 1 |
| Schroers, E | 1 |
| Büttner, R | 1 |
| Rücker, Av | 1 |
| Gütgemann, I | 1 |
| Sun, XF | 1 |
| Zhen, ZJ | 1 |
| Liu, DG | 1 |
| Xia, Y | 1 |
| Xiang, XJ | 1 |
| Chen, XQ | 1 |
| Ling, JY | 1 |
| Zheng, L | 1 |
| Luo, WB | 1 |
| Lin, H | 1 |
| He, YJ | 1 |
| Guan, ZZ | 1 |
| Mantadakis, E | 1 |
| Raissaki, M | 1 |
| Tzardi, M | 1 |
| Katzilakis, N | 1 |
| Chatzimichael, A | 1 |
| Kalmanti, M | 1 |
| Reiter, A | 3 |
| Schrappe, M | 3 |
| Parwaresch, R | 1 |
| Henze, G | 3 |
| Müller-Weihrich, S | 3 |
| Sauter, S | 1 |
| Sykora, KW | 1 |
| Ludwig, WD | 4 |
| Gadner, H | 2 |
| Riehm, H | 2 |
| Gassmann, W | 1 |
| Löffler, H | 1 |
| Fonatsch, C | 1 |
| Heil, G | 1 |
| Heinze, B | 1 |
| Arnold, R | 1 |
| Hossfeld, D | 1 |
| Büchner, T | 1 |
| Koch, P | 1 |
| Freund, M | 1 |
| Maschmeyer, G | 1 |
| Heyll, A | 1 |
| Aul, C | 1 |
| Faak, T | 1 |
| Kuse, R | 1 |
| Ittel, TH | 1 |
| Gramatzki, M | 1 |
| Diedrich, H | 1 |
| Kolbe, K | 1 |
| Fuhr, HG | 1 |
| Fischer, K | 1 |
| Schadeck-Gressel, C | 1 |
| Weiss, A | 1 |
| Strohscheer, I | 1 |
| Metzner, B | 1 |
| Fabry, U | 1 |
| Völkers, B | 1 |
| Messerer, D | 1 |
| Uberla, K | 1 |
| Geissler, RG | 1 |
| Bergmann, L | 1 |
| Hacker, H | 1 |
| Knupp, B | 1 |
| Walker, B | 1 |
| Yamao, H | 1 |
| Kondo, E | 1 |
| Miura, A | 1 |
| Mizuno, H | 1 |
| Yuge, M | 1 |
| Tiemann, M | 1 |
| Yakisan, E | 1 |
| Zimmermann, M | 1 |
| Mann, G | 1 |
| Chott, A | 1 |
| Ebell, W | 1 |
| Klingebiel, T | 1 |
| Graf, N | 1 |
| Kremens, B | 1 |
| Plüss, HJ | 1 |
| Zintl, F | 1 |
| Spreafico, F | 1 |
| Massimino, M | 1 |
| Luksch, R | 1 |
| Casanova, M | 1 |
| Cefalo, GS | 1 |
| Collini, P | 1 |
| Ferrari, A | 1 |
| Polastri, D | 1 |
| Terenziani, M | 1 |
| Gasparini, M | 1 |
| Fossati-Bellani, F | 1 |
| Lampert, F | 1 |
| Harbott, J | 1 |
| Niemeyer, CM | 1 |
| Ritter, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk)[NCT00974792] | Phase 2 | 150 participants (Anticipated) | Interventional | 2006-01-31 | Recruiting | ||
| A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma[NCT00392990] | Phase 2 | 25 participants (Actual) | Interventional | 2007-02-06 | Completed | ||
| Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)[NCT00199082] | Phase 4 | 650 participants (Anticipated) | Interventional | 2002-07-31 | Completed | ||
| Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma[NCT00392834] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma[NCT00040690] | Phase 2 | 120 participants (Anticipated) | Interventional | 2008-11-30 | Completed | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China[NCT02405676] | Phase 2/Phase 3 | 200 participants (Anticipated) | Interventional | 2015-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall Survival (OS) of patients with Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen. OS is defined from the first dose of study drug to the time of death for any reason. (NCT00392990)
Timeframe: At 2 years from treatment initiation Median follow up 34 months (range 15-45)
| Intervention | percentage of patients alive (Number) |
|---|---|
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | 81 |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | 100 |
Progression Free Survival (PFS) will be defined from the first dose of study drug to the first documentation of progressive disease or death for any reason. Patients that are lost to follow-up before progression will be censored at the point of last documentation of not experiencing the event. (NCT00392990)
Timeframe: At 2 years from treatment initiation. Median follow up 34 months (range 15-45)
| Intervention | percentage of patients progression free (Number) |
|---|---|
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | 76 |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | 100 |
"Response Rate is defined as combined number of patients with Complete Remission (CR) Complete Remission undetermined (Cru) and Partial Remission (PR) for patients with Burkitt's and Burkitt-like Lymphoma/Leukemia. Response will be measured by CT scans following treatment completion and assessed using Response Criteria for Non-Hodgkin's Lymphoma where:~CR=complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms.~CRu=same as above but allowing for 75% decrease in lymph node masses and indeterminate or normal bone marrow.~PR=50% decrease in SPD of the six largest dominant nodes or nodal masses with no increase in size or other nodes, liver, spleen and no new sites of disease." (NCT00392990)
Timeframe: After two cycles of treatment and at completion of treatment (4 cycles for high risk and 3 cycles for low risk) up to approximately 20 weeks.
| Intervention | percentage of patients (Number) | |
|---|---|---|
| ORR after two cycles of treatment | ORR at completion of treatment | |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | 100 | 100 |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | 100 | 100 |
"Adverse events (AE) graded as either 3 or 4 and determined to be at least possibly related to study treatment will be collected in patients Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen to assess the safety and toxicity profile of the addition of rituximab, subsitution of adriamycin for doxil and lower dose of methotrexate. AEs will be assessed as follows at the following time points: At the end of each cycle or monthly whichever is less frequent and 30 days post last dose of study treatment for a maximum of 3 cycles for regimen A and 4 cycles for regimen B and up to 12 months.~In general AEs will be assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v 3.0). In general adverse events (AEs) will be graded according to the following:~Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE" (NCT00392990)
Timeframe: After each cycle or monthly (whichever is less frequent), 30 days post last dose. Treatment duration was at a median of 13 weeks (range 11-20) for high-risk patients and 10 weeks (range 9-12) for low-risk patients.
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia : Grade 3 | Anemia : Grade 4 | Neutropenia : Grade 3 | Neutropenia : Grade 4 | Thrombocytopenia : Grade 3 | Thrombocytopenia : Grade 4 | Mucositis : Grade 3 | Mucositis : Grade 4 | Infection : Grade 3 | Infection : Grade 4 | Elevated Transaminases : Grade 3 | Elevated Transaminases : Grade 4 | Fever (Neutropenic) : Grade 3 | Fever (Neutropenic) : Grade 4 | Low Phosphate : Grade 3 | Low Phosphate : Grade 4 | Sodium Abnormalities : Grade 3 | Sodium Abnormalities : Grade 4 | Hyperglycemia : Grade 3 | Hyperglycemia : Grade 4 | Hypoalbuminemia : Grade 3 | Hypoalbuminemia : Grade 4 | Hypokalemia : Grade 3 | Hypokalemia : Grade 4 | Cardiac : Grade 3 | Cardiac : Grade 4 | Diarrhea : Grade 3 | Diarrhea : Grade 4 | Elevated Creatinine : Grade 3 | Elevated Creatinine : Grade 4 | Nausea/Vomiting : Grade 3 | Nausea/Vomiting : Grade 4 | Low Blood Pressure : Grade 3 | Low Blood Pressure : Grade 4 | Rash : Grade 3 | Rash : Grade 4 | Edema : Grade 3 | Edema : Grade 4 | Low Magnesium : Grade 3 | Low Magnesium : Grade 4 | |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | 13 | 1 | 5 | 6 | 1 | 13 | 7 | 3 | 8 | 0 | 6 | 0 | 4 | 0 | 5 | 0 | 4 | 0 | 1 | 5 | 4 | 0 | 1 | 0 | 3 | 0 | 2 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | 3 | 0 | 2 | 2 | 1 | 2 | 2 | 0 | 1 | 0 | 2 | 0 | 3 | 0 | 1 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
(NCT00392834)
Timeframe: 1 year post treatment
| Intervention | Cumulative proportion surviving at 1 yr (Number) |
|---|---|
| Regimen A (R-CODOX-M Chemotherapy) | 1.0 |
| Regimen B (Rituximab and IVAC Chemotherapy) | 0.82 |
8 reviews available for ifosfamide and African Lymphoma
| Article | Year |
|---|---|
Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2013 |
[Treatment strategy of gray zone lymphomas].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2014 |
Adult Burkitt lymphoma: advances in diagnosis and treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2008 |
[Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Challenges in the management of Burkitt's lymphoma.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly A | 2002 |
Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cyt | 2003 |
Ifosfamide in hematological malignancies of adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Hematologic Neoplasms; Hodgkin Disease; | 2003 |
Ifosfamide neuropsychiatric toxicity in patients with cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Delusions; Enzyme Inhibitors; Female; Hu | 2007 |
13 trials available for ifosfamide and African Lymphoma
| Article | Year |
|---|---|
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2020 |
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carbopl | 2019 |
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine- | 2014 |
AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antir | 2015 |
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine | 2008 |
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cohort Studies; | 2010 |
Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.
Topics: Adolescent; Adult; Africa South of the Sahara; Antineoplastic Combined Chemotherapy Protocols; Burki | 2012 |
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabin | 2002 |
Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2004 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1995 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System | 2002 |
26 other studies available for ifosfamide and African Lymphoma
| Article | Year |
|---|---|
Primary intradural extramedullary spinal Burkitt's lymphoma mimicking a nerve sheath tumor: a case report.
Topics: Burkitt Lymphoma; Cytarabine; Humans; Ifosfamide; Male; Middle Aged; Nerve Sheath Neoplasms; Treatme | 2022 |
Nivolumab Treatment of Burkitt Lymphoma: A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Cyclophos | 2021 |
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustin | 2018 |
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2018 |
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
How I treat Burkitt lymphoma in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabin | 2014 |
A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Burkitt Lymphoma; Cycloph | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cycl | 2016 |
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Successful treatment of ICE-rituximab chemotherapy and subsequent bone marrow transplantation in a patient with early-relapse Burkitt leukemia and inverted duplication of 1q.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2012 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 2003 |
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabin | 2003 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Treatment of Burkitt's lymphoma during pregnancy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cycl | 2006 |
CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
[Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
Absent immunoglobulins in HIV-related Burkitt lymphoma/leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; B-Lymphocytes | 2008 |
[Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
Primary hepatic Burkitt lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2008 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Severe central nervous adverse effect of intrathecal chemotherapy in a 16-yr-old patient with Burkitt's type lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain; Burkitt Lymphoma; Central Nervous | 1997 |
[Successful treatment with high dose chemotherapy following peripheral blood stem cell transplantation for relapsed Burkitt's lymphoma with central nervous system involvement].
Topics: Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; | 1998 |
Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1992 |